Datavant, which lets healthcare organizations connect their data while protecting patient privacy, raises $40M Series B, bringing its total raised to $83M
Datavant, a San Francisco, CA-based provider of solutions for life sciences and healthcare organizations to connect their data …
Context & Ripple Effects
Datavant's $40M Series B lands in the middle of a funding run for health-data infrastructure. Earlier the same year, Innovaccer raised a $70M Series C to unify patient records across insurers and pharmacies, and Verana Health had already pulled $30M to run clinical-study analysis on real-world data — investors were consistently rewarding companies that solve how fragmented health data gets joined.
What separates Datavant is that it attacks the join problem from the privacy side: connecting datasets for life-sciences and healthcare customers without exposing patient identities. That positioning matters because every other round in this cluster — including HealthVerity's later $100M Series D — presumes buyers want linked patient data but face tightening constraints on how it can be handled.
First-order effects
- Datavant gets runway to scale its privacy-preserving record-linkage product for life-sciences clients at $83M total raised, while competitors like Innovaccer and HealthVerity are raising even larger sums into adjacent parts of the same workflow.
- Pharma and healthcare organizations evaluating data vendors now have a funded neutral option whose core pitch is linkage without identity exposure, alongside platforms that aggregate raw records.
Second-order effects
- Vendors holding identifiable or lightly-de-identified datasets face pressure to add tokenization-style matching, since a well-funded privacy-first rival can win deals where data-sharing agreements stall.
- Pricing power shifts toward whoever controls the match key: if life-sciences analysts standardize on one linkage layer, dataset owners must integrate with it to stay addressable.
Third-order effects
- Health-data infrastructure is stratifying into aggregation layers (Innovaccer, HealthVerity) and privacy/connectivity layers (Datavant), with each startup's fundraising pushing the industry toward interoperability built on de-identified matching rather than direct record exchange.
- If the pattern holds, the durable moats in this market belong to whoever becomes the standard handshake between datasets — an outcome regulators' privacy requirements would reinforce rather than block.
The trend: Venture capital is consolidating around health-data interoperability, with privacy-preserving linkage emerging as the layer through which life-sciences data must pass.